A phase 3b, long-term, observational study of the durability of seroconversion in patients with chronic hepatitis B virus infection who have seroconverted while participating in a previous Gilead-sponsored study of adefovir dipivoxil

Trial Profile

A phase 3b, long-term, observational study of the durability of seroconversion in patients with chronic hepatitis B virus infection who have seroconverted while participating in a previous Gilead-sponsored study of adefovir dipivoxil

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Adefovir dipivoxil (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 10 Jan 2014 Status changed from active, no longer recruiting to completed as reported in ClinicalTrials.gov record.
    • 26 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top